These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 23699256)

  • 1. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.
    McNeil LK; Zagursky RJ; Lin SL; Murphy E; Zlotnick GW; Hoiseth SK; Jansen KU; Anderson AS
    Microbiol Mol Biol Rev; 2013 Jun; 77(2):234-52. PubMed ID: 23699256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB) Vaccines.
    Tzeng YL; Giuntini S; Berman Z; Sannigrahi S; Granoff DM; Stephens DS
    Infect Immun; 2020 Nov; 88(12):. PubMed ID: 32958529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6.
    Bianchi F; Veggi D; Santini L; Buricchi F; Bartolini E; Lo Surdo P; Martinelli M; Finco O; Masignani V; Bottomley MJ; Maione D; Cozzi R
    FASEB J; 2019 Nov; 33(11):12099-12111. PubMed ID: 31442074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional impacts of the diversity of the meningococcal factor H binding protein.
    Hong E; Giorgini D; Deghmane AE; Taha MK
    Vaccine; 2012 Dec; 31(1):183-9. PubMed ID: 23123023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
    Pajon R; Lujan E; Granoff DM
    Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
    Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS
    Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad vaccine protection against Neisseria meningitidis using factor H binding protein.
    Findlow J; Bayliss CD; Beernink PT; Borrow R; Liberator P; Balmer P
    Vaccine; 2020 Nov; 38(49):7716-7727. PubMed ID: 32878710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?
    Granoff DM; Ram S; Beernink PT
    Clin Vaccine Immunol; 2013 Aug; 20(8):1099-107. PubMed ID: 23740919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1.
    Marini A; Rossi O; Aruta MG; Micoli F; Rondini S; Guadagnuolo S; Delany I; Henderson IR; Cunningham AF; Saul A; MacLennan CA; Koeberling O
    PLoS One; 2017; 12(7):e0181508. PubMed ID: 28742866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.
    Veggi D; Bianchi F; Santini L; Lo Surdo P; Chesterman CC; Pansegrau W; Bechi N; Huang Y; Masignani V; Pizza M; Rappuoli R; Bottomley MJ; Cozzi R; Maione D
    PLoS Pathog; 2020 Oct; 16(10):e1008882. PubMed ID: 33007046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
    Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
    Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
    Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
    Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two human antibodies to a meningococcal serogroup B vaccine antigen enhance binding of complement Factor H by stabilizing the Factor H binding site.
    Sands NA; Beernink PT
    PLoS Pathog; 2021 Jun; 17(6):e1009655. PubMed ID: 34125873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines.
    Beernink PT; Granoff DM
    Infect Immun; 2008 Jun; 76(6):2568-75. PubMed ID: 18362128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
    Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis.
    Lewis LA; Vu DM; Vasudhev S; Shaughnessy J; Granoff DM; Ram S
    mBio; 2013 Oct; 4(5):e00339-13. PubMed ID: 24129254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal factor H binding protein as immune evasion factor and vaccine antigen.
    Principato S; Pizza M; Rappuoli R
    FEBS Lett; 2020 Aug; 594(16):2657-2669. PubMed ID: 32298465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.
    Beernink PT; Ispasanie E; Lewis LA; Ram S; Moe GR; Granoff DM
    J Infect Dis; 2019 Mar; 219(7):1130-1137. PubMed ID: 30346576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.
    Beernink PT; Shaughnessy J; Braga EM; Liu Q; Rice PA; Ram S; Granoff DM
    J Immunol; 2011 Mar; 186(6):3606-14. PubMed ID: 21325619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.